Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenesis, Mass General Researcher Launch Proteomics-Based Partnership

NEW YORK, July 23-Massachusetts General Hospital and NeoGenesis Pharmaceuticals announced today a four-year proteomics-based drug discovery collaboration.

Through the partnership, MGH molecular biologist Brian Seed will provide the company with proteins believed to play a role in disease.  NeoGenesis will use its compound libraries and ligand screening system to identify compounds that interact with these proteins. MGH will characterize the compounds in assays and animal models, and NeoGenesis will take over clinical development.


The partners will look for drugs to target cancer and inflammatory disease. Financial details were not disclosed.


Seed studies gene expression in angiogenesis and signal transduction in the immune response, and has a proteomics facility in Cambridge, Mass that can produce and characterize disease-associated proteins.


The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.